Resveratrol protects β amyloid-induced oxidative damage and memory associated proteins in H19-7 hippocampal neuronal cells

Current Alzheimer Research

Volumn 12, Issue 2, 2015, Pages 147-156

  Rege, Shraddha D ^a   Geetha, Thangiah ^b   Broderick, Tom L ^c   Babu, Jeganathan Ramesh ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY AT MONTGOMERY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer s disease; Insulin resistance; Memory; Oxidative stress; Resveratrol; Type 2 diabetes; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; ANTIOXIDANT; ARC PROTEIN; ASCORBIC ACID; CATALASE; CELL PROTEIN; GLUTATHIONE; GLUTATHIONE REDUCTASE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULINASE; LIPID PEROXIDE; MEMBRANE PROTEIN; MEMORY ASSOCIATED PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; RESVERATROL; SUPEROXIDE DISMUTASE; TAU PROTEIN; TOCOPHEROL; UNCLASSIFIED DRUG; ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN; CYTOSKELETON PROTEIN; DLGH4 PROTEIN, RAT; MAPT PROTEIN, RAT; NERVE PROTEIN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; SIGNAL PEPTIDE; STILBENE DERIVATIVE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ATTENUATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; IN VITRO STUDY; LIPID PEROXIDATION; MEMORY DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYNAPSE; UPREGULATION; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RAT; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; CELL LINE; CYTOSKELETAL PROTEINS; HIPPOCAMPUS; INSULYSIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID PEROXIDATION; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; STILBENES; TAU PROTEINS;

EID: 84939567861     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150204130009     Document Type: Article

References (71)

1. Kolarova M, García-Sierra F, Bartos A, Ricny J, Ripova D. Structure and Pathology of Tau Protein in Alzheimer Disease. Int J Alzheimer’s Dis 2012: 731526 (2012).
2. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 10(9): 819-28 (2011).
3. Huang T-C, Lu K-T, Wo Y-YP, Wu Y-J, Yang Y-L. Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PloS One 6(12): (2011).
4. Selkoe DJ. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis JAD 3(1):75-80 (2001).
5. Selkoe DJ. Deciphering the genesis and fate of amyloid betaprotein yields novel therapies for Alzheimer disease. J Clin Invest 110(10):1375-81 (2002).
6. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic Biol Med 43(5): 658-77 (2007).
7. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3 (3): 205-14 (2004).
8. Rege SD, Kumar S, Wilson DN, Tamura L, Geetha T, Mathews ST, et al. Resveratrol protects the brain of obese mice from oxidative damage. Oxid Med Cell Longev 2013: 419092 (2013).
9. Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and significance in human body. Indian J Exp Biol 40(11): 1233-9 (2002).
10. Li H, Xia N, Förstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide Biol Chem Off J Nitric Oxide Soc 26(2): 102-10 (2012).
11. Zhang F, Wang H, Wu Q, Lu Y, Nie J, Xie X, et al. Resveratrol protects cortical neurons against microglia-mediated neuroinflammation. Phytother Res PTR 27(3): 344-9 (2013).
12. Bertelli AA, Ferrara F, Diana G, Fulgenzi A, Corsi M, Ponti W, et al. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiin flammatory and anticancer chemopreventive activity. Int J Tissue React 21(4): 93-104 (1999).
13. Cleary J, Hittner JM, Semotuk M, Mantyh P, O’Hare E. Betaamyloid(1-40) effects on behavior and memory. Brain Res 682: 69-74 (1995).
14. Lu X, Ma L, Ruan L, Kong Y, Mou H, Zhang Z, et al. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 7: 46 (2010).
15. Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 8: 25-33 (2009).
16. Högberg J, Larson RE, Kristoferson A, Orrenius S. NADPHdependent reductase solubilized from microsomes by peroxidation and its activity. Biochem Biophys Res Commun 56 (3): 836-42 (1974).
17. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem FEBS 47(3): 469-74 (1974).
18. Sinha AK. Colorimetric assay of catalase. Anal Biochem 47(2): 389-94 (1972).
19. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 179(4073): 588-90 (1973).
20. Staal GEJ, Visser J, Veeger C. Purification and properties of glutathione reductase of human erythrocytes. Biochim Biophys Acta BBA - Enzymol 185(1): 39-48 (1969).
21. Ells HA, Kirkman HN. A colorimetric method for assay of erythrocytic glucose-6-phosphate dehydrogenase. Proc Soc Exp Biol Med Soc Exp Biol Med NYN 106: 607-9 (1961).
22. Quaife ML, Scrimshaw NS, Lowry OH. A micromethod for assay of total tocopherols in blood serum. J Biol Chem 180(3): 1229-35 (1949).
23. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 582(1): 67-78 (1979).
24. Kairisalo M, Bonomo A, Hyrskyluoto A, Mudò G, Belluardo N, Korhonen L, et al. Resveratrol reduces oxidative stress and cell death and increases mitochondrial antioxidants and XIAP in PC6.3- cells. Neurosci Lett 488(3): 263-6 (2011).
25. Nguyen NTQ, Ooi L, Piller SC, Münch G. Proenergetic effects of resveratrol in the murine neuronal cell line Neuro2a. Mol Nutr Food Res 57(11): 1901-7 (2013).
26. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol 591(1): 66-72 (2008).
27. Hsu M-H, Savas U, Lasker JM, Johnson EF. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. J Pharmacol Exp Ther 337: 125-36 (2011).
28. Sakata Y, Zhuang H, Kwansa H, Koehler RC, Doré S. Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp Neurol 224(1): 325-9 (2010).
29. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol (Berl) 119(5): 523-41 (2010).
30. Shao CY, Mirra SS, Sait HBR, Sacktor TC, Sigurdsson EM. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease. Acta Neuropathol (Berl) 122(3): 285-92 (2011).
31. Dorostkar MM, Herms J. Arc illuminates Alzheimer’s pathophysiology. Nat Neurosci 15(10): 1323-5 (2012).
32. Eng LF, Ghirnikar RS, Lee YL. Glial Fibrillary Acidic Protein: GFAP-Thirty-One Years (1969-2000). Neurochem Res 25: 1439-51 (2000).
33. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88(4): 640-51 (2014).
34. Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108: 21-43 (2013).
35. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde Y-A, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86(3): 582-90 (2003).
36. LLorens-Martin M, Jurado J, Hernandez F, Avila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 7: 46 (2014).
37. Hohman TJ, Koran MEI, Thornton-Wells TA, Alzheimer’s Neuroimaging Initiative. Interactions between GSK3β and amyloid genes explain variance in amyloid burden. Neurobiol Aging 35(3): 460-5 (2014).
38. Jang J-H, Surh Y-J. Protective effect of resveratrol on betaamyloid- induced oxidative PC12 cell death. Free Radic Biol Med 34(8): 1100-10 (2003).
39. Calvo-Ochoa E, Arias C. Cellular and metabolic alterations in the hippocampus caused by insulin signaling dysfunction and its association with cognitive impairment during aging and Alzheimer’s disease. Animal models of study. Diabetes Metab Res Rev (2014).
40. Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and brain health. Neuromolecular Med 10(4): 259-74 (2008).
41. Gemma C, Vila J, Bachstetter A, Bickford PC. Oxidative Stress and the Aging Brain: From Theory to Prevention. In: Riddle DR, editor. Brain Aging Models Methods Mech., Boca Raton (FL): CRC Press (2007).
42. Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, Bartolo M, et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 61: 215-26 (2013).
43. Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci Lett 281: 123-6 (2000).
44. Tadolini B, Juliano C, Piu L, Franconi F, Cabrini L. Resveratrol inhibition of lipid peroxidation. Free Radic Res 33(1): 105-14 (2000).
45. Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, Ding Q. Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem Cell Biol 36(12): 2376-91 (2004).
46. Dincer Y, Akcay T, Alademir Z, Ilkova H. Effect of oxidative stress on glutathione pathway in red blood cells from patients with insulin-dependent diabetes mellitus. Metabolism 51(10): 1360-2 (2002).
47. Lykkesfeldt J, Moos T. Age-dependent change in Vitamin C status: a phenomenon of maturation rather than of ageing. Mech Ageing Dev 126(8): 892-8 (2005).
48. Traber MG, Stevens JF. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med 51(5): 1000-13 (2011).
49. Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63(7): 1187-92 (2004).
50. Schrijvers EMC, Witteman JCM, Sijbrands EJG, Hofman A, Koudstaal PJ, Breteler MMB. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 75(22):1982-7 (2010).
51. Moreira RO, Campos SC, Soldera AL. Type 2 Diabetes Mellitus and Alzheimer’s Disease: from physiopathology to treatment implications. Diabetes Metab Res Rev (2013).
52. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66(3): 300-5 (2009).
53. Zhao W-Q, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490: 71-81 (2004).
54. Van der Heide LP, Kamal A, Artola A, Gispen WH, Ramakers GMJ. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidylinositol- 3-kinase-dependent manner. J Neurochem 94(4): 1158-66 (2005).
55. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100(7): 4162-7 (2003).
56. Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, et al. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer’s disease transgenic mice. J Neurosci Off J Soc Neurosci 30(43): 14299-304 (2010).
57. Hol EM, Roelofs RF, Moraal E, Sonnemans M A F, Sluijs JA, Proper EA, et al. Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms. Mol Psychiatry 8(9): 786-96 (2003).
58. Leuba G, Walzer C, Vernay A, Carnal B, Kraftsik R, Piotton F, et al. Postsynaptic density protein PSD-95 expression in Alzheimer’s disease and okadaic acid induced neuritic retraction. Neurobiol Dis 30(3): 408-19 (2008).
59. Kerrigan TL, Randall AD. A new player in the “synaptopathy” of Alzheimer’s disease - arc/arg 3.1. Front Neurol 4: 9 (2013).
60. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation. J Neurosci 23(18): 7084-92 (2003).
61. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer’s disease: molecular links & clinical implications. Curr Alzheimer Res 5(5): 438-47 (2008).
62. Phiel CJ, Wilson CA, Lee VM-Y, Klein PS. GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature 423: 435-9 (2003).
63. Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 99: 195-231 (1992).
64. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener 6: 85 (2011).
65. Bhargava A, Mathias RS, McCormick JA, Dallman MF, Pearce D. Glucocorticoids prolong Ca(2+) transients in hippocampal-derived H19-7 neurons by repressing the plasma membrane Ca(2+)- ATPase-1. Mol Endocrinol Baltim Md 16: 1629-37 (2002).
66. Eves EM, Tucker MS, Roback JD, Downen M, Rosner MR, Wainer BH. Immortal rat hippocampal cell lines exhibit neuronal and glial lineages and neurotrophin gene expression. Proc Natl Acad Sci USA 89: 4373-7 (1992).
67. Morrione A, Romano G, Navarro M, Reiss K, Valentinis B, Dews M, et al. Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells. Cancer Res 60: 2263-72 (2000).
68. Shin MK, Kim HG, Kim KL. A novel trimeric peptide, Neuropep- 1-stimulating brain-derived neurotrophic factor expression in rat brain improves spatial learning and memory as measured by the Ymaze and Morris water maze. J Neurochem 116(2): 205-16 (2011).
69. Jung WR, Kim HG, Shin MK, Park DI, Kim KL. The effect of ganglioside GQ1b on the NMDA receptor signaling pathway in H19-7 cells and rat hippocampus. Neuroscience 165(1): 159-67 (2010).
70. Pugazhenthi S, Nesterova A, Jambal P, Audesirk G, Kern M, Cabell L, et al. Oxidative stress-mediated down-regulation of bcl-2 promoter in hippocampal neurons. J Neurochem 84: 982-96 (2003).
71. Oh D-Y, Cho JH, Park S-Y, Kim YS, Yoon Y-J, Yoon SH, et al. A novel role of hippocalcin in bFGF-induced neurite outgrowth of H19-7 cells. J Neurosci Res 86(7):1557-65 (2008).